On May 13, 2024, Edgar G. Engleman, M.D. notified the Bolt Biotherapeutics, Inc. of his resignation as a member of Board and from all committees of the Board on which he served, effective as of May 15, 2024. Upon his departure as a member of the Board, Dr. Engleman joined the Company's Scientific Advisory Board to continue to provide his support to the Company with his extensive expertise and experience in the biopharmaceutical industry. Effective as of May 15 2024, Randall C. Schatzman, Ph.D. resigned as a member of the Board.
Dr. Schatzman will continue to be an employee of the Company through July 15, 2024, at which time he will become an advisor to the Company pursuant to a consulting agreement entered into on May 13, 2024. Effective as of May 15, 2024, Edith A. Perez, M.D. stepped down as the Company?s Chief Medical Officer, as the Company eliminated the position of Chief Medical Officer. Dr. Perez will continue to be an employee of the Company through July 15, 2024, at which time she will become an advisor to the Company pursuant to a consulting agreement entered into on May 13, 2024.
Effective May 15, 2024, William P. Quinn, the Company's Chief Financial Officer since 2020, also became the Company's President and was appointed a member of the Board as a Class II director. Effective May 15, 2024, Grant Yonehiro, the Company's Chief Business Officer since 2016, became the Company's Chief Operating Officer.
